JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/100/0.1/21.06.24

JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/100/0.1/21.06.24 Share Price

Warrant

DE000JS0VXT6

Market Closed - Börse Stuttgart 02:51:24 10/05/2024 pm IST
0.001 ^EUR	-.--%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/100/0.1/21.06.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment	14/06	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	14/06	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	14/06	DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	14/06	BU

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	J.P. Morgan
WKN	JS0VXT
ISIN	DE000JS0VXT6
Date issued	02/11/2022
Strike	100 $
Maturity	21/06/2024 (6 Days)
Parity	10 : 1
Emission price	0.36 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.43 €
Lowest since issue	0.001 €

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company